Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma

Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma

In the biology of multiple myeloma (MM), immune dysregulation has emerged as a critical component for novel therapeutic strategies. This dysfunction is due to a reduced antigen presentation, a reduced effector cell ability and a loss of reactive T cells against myeloma, together with a bone marrow m...

Full description

Bibliographic Details
Main Authors: Stefania Oliva, Rossella Troia, Mattia D'Agostino, Mario Boccadoro, Francesca Gay
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-11-01
Series:Frontiers in Immunology
Subjects:
multiple myeloma
PD-1
PD-L1
immune dysregulation
T cells
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2018.02749/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2018.02749/full

Similar Items